SARS-CoV-2 Nucleocapsid Antibody (84C4a)

ELISA: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - Microtiter wells were coated with SARS-CoV-2 Nucleocapsid and SARS-CoV Nucleocapsid at 1 ug/ml. Purified rabbit monoclonal antibodies were serially diluted 1:2 starting at 1 ug/ml, showing very strong and specific binding to SARS-CoV-2 Nucleocapsid antigen, with no significant cross-reactivity to SARS-CoV Nucleocapsid antigen.

Sandwich ELISA: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - A sandwich ELISA was performed using SARS-CoV-2 Nucleocapsid specific rabbit monoclonal antibodies: capture antibody and biotin-conjugated a detection antibody. SARS-CoV-2 Nucleocapsid was serially diluted 1:2 starting at 25 ng/ml. The capture antibody and biotin-conjugated a detection antibodies detected SARS-CoV-2 Nucleocapsid antigen at very high sensitivity as low as 100 pg/ml (100 pg).

ELISA: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - A sandwich ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid Protein (NP) specific rabbit monoclonal antibodies: 84C4a as a capture antibody and75G5a-biotin as a detection antibody. COVID-19 NP was serially diluted 1:2 starting at 25 ng/mL. Rabbit monoclonal antibodies 84C4a and 75G5a-biotin detectedCOVID-19 NP antigen at very high sensitivity as low as 49 pg/mL (4.9 pg).

Western Blot: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - Western blot analysis of SARS-CoV2 and SARS-CoV nucleocapsid protein (50 ng) probed with 1 ug/mL CoV2NP rabbit monoclonal antibody (84C4a), CoV2NP-84C4.

Immunohistochemistry: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Nucleocapsid antibody (, 5 ng/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 Nucleocapsid protein was observed in the macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.

ELISA: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - Microtiter wells were coated with SARS-CoV-2 (COVID-19) Nucleocapsid Protein (NP) and SARS-CoV NP at 1 ug/mL. Purified rabbit monoclonal antibody 84C4a wasserially diluted 1:2 starting at 1 ug/mL, and shows very strong and specific binding to COVID-19 NP antigen, with no significant cross-reactivity to SARS-CoV NP antigen.

ELISA: SARS-CoV-2 Nucleocapsid Antibody (84C4a) [NBP3-07041] - A sandwich ELISA was performed using SARS-CoV-2 (COVID-19) Nucleocapsid Protein (NP) specific rabbit monoclonal antibodies: 84C4a as a capture antibody and75G5a-biotin as a detection antibody. COVID-19 NP was serially diluted 1:2 starting at 25 ng/mL. Rabbit monoclonal antibodies 84C4a and 75G5a-biotin detectedCOVID-19 NP antigen at very high sensitivity as low as 49 pg/mL (4.9 pg).

• Reactivity: V
• Applications: ELISA
• Clone: 84C4a
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

SARS-CoV-2 Nucleocapsid Antibody (84C4a) Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: SARS-CoV-2 nucleoprotein (NP) specific peptide
• Isotype: IgG Kappa
• Clonality: Monoclonal
• Host: Rabbit
• Gene: N
• Purity: Peptide affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Sandwich ELISA
• Application Notes: Used for specific, high-sensitivity detection of SARS-CoV-2 nucleocapsid protein (NP).

Reactivity Notes

Highly-specific to SARS-CoV-2 nucleoprotein; does not cross-react with nucleoprotein from SARS-CoV or other coronaviruses

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS, 50% Glycerol, 0.1% BSA
• Preservative: 0.02% Sodium Azide
• Purity: Peptide affinity purified

Alternate Names for SARS-CoV-2 Nucleocapsid Antibody (84C4a)

• 2019-nCoV N Protein
• 2019-nCoV Nucleocapsid Protein
• COVID-19 N protein
• COVID-19 nucleocapsid protein
• Human coronavirus Nucleoprotein
• nucleocapsid phosphoprotein
• Nucleocapsid protein
• Nucleoprotein
• ORF9; structural protein
• SARS-CoV-2 Nucleocapsid protein
• SARS-CoV-2 N protein
• SARSCoV2 Nucleoprotein
• SARS-CoV-2
• Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein

Background

The SARS-CoV-2 Nucleocapsid protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The nucleocapsid protein is an RNA-binding protein that is essential for viral assembly into a ribonucleoprotein complex and also functions in viral budding (2,3). More specifically, after viral replication and RNA synthesis, the viral genomes that are encapsulated by the nucleocapsid protein will bud into the membrane and help with mature virus formation (2). The nucleocapsid protein is synthesized as 419 amino acids (aa) in length with a theoretical molecular weight of 45.6 kDa (4). Structurally, the nucleocapsid protein contains an RNA-binding domain (N1b), a dimerization domain (N2b), and a few shorter regions (N1a, N2a, and spacer B/N3) (3). It is the N1b domain that is suggested to be involved in RNA binding (3). The nucleocapsid N1b domain contains a beta-hairpin, a loop region, and a beta-sheet core, giving it a right-handed shape (3). Conversely, the N2b domain functions in dimerization which promotes assembly into a helical filament where the dimer interface is made of two beta-strands and an alpha-helix portion (3). Inhibition of nucleocapsid assembly may be a potential target for treating COVID-19 infection.

Following SARS-CoV-2 infection, B cells and T cells display an immune response against nucleocapsid protein and nucleocapsid-specific neutralizing antibodies are produced (5). Interestingly, a study of patients who have recovered from COVID-19 revealed that there were no neutralizing antibodies against nucleocapsid protein present; however, a high presence against neutralizing spike RBD antibodies were detected (5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. https://doi.org/10.1016/j.crmicr.2020.06.003

4. Uniprot (P0DTC9)

5. Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01949

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: N